Abstract CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16)

The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Sarina Piha-Paul, Johanna C. Bendell, Anthony Tolcher, Rachna Shroff, Paula R. Pohlmann, Sara A. Hurvitz, Anuradha Krishnamurthy, Naimish Pandya, Shane A. Olwill, Markus Zettl, Kayti Aviano, Lynn Mar, Patrick Jolicoeur, Aizea Morales Kastresana, Corinna Schlosser, Ingmar Bruns, Alice Bexon, Geoffrey Y. Ku. Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT017.